Clinical Studies| Volume 17, ISSUE 5, P827-837, September 1995

Download started.


Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis

      This paper is only available as a PDF. To read, Please Download here.


      This study evaluated physicians' use of the occurrence of tinnitus as a tool to establish the optimal dosage of salsalate, a nonacetylated salicylate, in patients with arthritis treated in routine clinical practice. The use of printed educational materials to improve compliance was also studied prospectively. A total of 782 patients were enrolled in this 3-week study by 95 general practitioners in an office setting. Of the 771 assessable patients, 90.0% had osteoarthritis, 9.7% had rheumatoid arthritis, and 0.3% had both types of arthritis. Most patients experienced improvement of symptoms after 3 weeks of treatment. There were no differences in the rates of improvement at the first and third weeks of treatment between patients with osteoarthritis and patients with rheumatoid arthritis. In addition, duration of arthritis had no effect on rates of improvement. Rates of patient satisfaction tended to increase over the study period. Rates of patient satisfaction did not differ significantly at the first and third weeks between patients who did receive printed educational materials and those who did not. Treatment was discontinued in 234 patients (30.4%) because of side effects. The most frequent reasons for discontinuation were gastrointestinal symptoms (n = 102; 13.2%) and tinnitus (n = 52; 6.7%). The clinical effectiveness and safety of salsalate were confirmed in patients with arthritis in routine clinical practice settings.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lee P
        • Tan LJP
        Drug compliance in outpatients with rheumatoid arthritis.
        Aust N Z J Med. 1979; 9: 274-277
        • Stoy DB
        Ensuring compliance to dietary and drug regimens.
        in: LaRosa JC Practical Management of Lipid Disorders. Health Care Communications, Inc, Fort Lee, NJ1992: 153-168
        • Tucker M
        • Kirwan JR
        Does patient education in rheumatoid arthritis have therapeutic potential?.
        Ann Rheum Dis. 1991; 50: 422-428
        • Liyanage SP
        • Tambar PK
        Comparative study of salsalate and aspirin in osteoarthrosis of the hip or knee.
        Curr Med Res Opin. 1978; 5: 450-453
        • Nordovist P
        Disalicylic acid.
        Aktuelle Gerontol. 1976; 6: 31-36
        • Roth S
        • Bennett R
        • Caldron P
        • et al.
        Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate).
        Semin Arthritis Rheum. 1990; 19 (Suppl 2): 11-19
        • Montrone E
        • Caruso I
        • Cazzola M
        Salsalate in the treatment of rheumatoid arthritis: A double-blind clinical and gastroscopic trial versus piroxicam. I-Clinical trial.
        J Int Med Res. 1989; 17: 316-319
        • Deodhar SD
        • McLeod MM
        • Dick WC
        • et al.
        A short-term comparative trial of salsalate and indomethacin in rheumatoid arthritis.
        Curr Med Res Opin. 1977; 5: 185-188
        • Bombardier C
        • Peloso C
        • Goldsmith C
        • et al.
        Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis.
        J Rheumatol. 1995; 4: 617-624
        • Mongan E
        • Kelly P
        • Nies K
        • et al.
        Tinnitus as an indication of therapeutic serum salicylate levels.
        JAMA. 1973; 226: 142
        • Cohen A
        Fecal blood loss and plasma salicylate study of salicylsalicylic acid and aspirin.
        Curr Ther Res. 1978; 19: 242-247
        • Scheiman JM
        • Behler EM
        • Berardi RR
        • et al.
        Salicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin: An endoscopic comparison.
        Dig Dis Sci. 1989; 34: 229-232
        • Halla JT
        • Hardin JG
        Salicylate ototoxicity in patients with rheumatoid arthritis: A controlled study.
        Ann Rheum Dis. 1988; 47: 134-137
        • Arnett FC
        • Edworthy S
        • Block DA
        • et al.
        The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
        Arthritis Rheum. 1988; 31: 315-324
        • Spiegal M
        2nd ed. Statistics. McGraw-Hill, New York1990: 245-265
        • Roth SH
        NSAIDs and gastropathy: A rheumatologist's view.
        J Rheumatol. 1988; 15: 912-919
        • April PA
        • Abeles M
        • Baraf HSB
        • et al.
        Does the acetyl group of aspirin contribute to the anti-inflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis?.
        J Rheumatol. 1989; 16: 321-327